首页 > 最新文献

European Heart Journal - Quality of Care and Clinical Outcomes最新文献

英文 中文
Trends and risk factors analysis of aortic aneurysm mortality in China over thirty years: based on the global burden of disease 2019 data.
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-30 DOI: 10.1093/ehjqcco/qcae084
Hongliang Huang, Liming Tang, Chunjiang Liu, Gan Jin

Objectives: This study aims to analyze the variation in mortality burden of aortic aneurysms (AA) and explore the associated risk factors based on Global Burden of Disease (GBD) 2019 data, investigating the mortality burden of AA in China.

Methods: Using GBD 2019 data, the mortality burden of AA in China from 1990 to 2019 was analyzed. The age-period-cohort model was utilized to analyze time trends, period, and cohort effects of 4 attributable risk factors of AA by age.

Results: In 2019, the total number of AA deaths in China increased by 136.1% compared to 1990, while the age-standardized mortality rate (ASMR) decreased by 6.8%. Male deaths and ASMR were higher than those of females, and ASMR increased with age. Whether viewed overall (Average Annual Percent Change (AAPC): -0.261, 95% Confidence Interval (CI): -0.383 to -0.138) or by sex (female AAPC: -0.812, 95% CI: -0.977 to -0.646; male AAPC: -0.011, 95% CI: -0.183 to 0.162), the ASMR for AA in China has shown a declining trend since 1990. Attributable risk factors such as high blood pressure, a diet high in sodium, smoking, and lead exposure increase AA mortality with age. Smoking mortality peaks between ages 80-85. The cyclical effect of high blood pressure on AA mortality significantly increases, while the cyclical effects of the other three risk factors decrease. For the population born after 1940, the cohort effect of high systolic blood pressure (SBP), a diet high in sodium, and smoking increased, while the cohort effect of lead exposure decreased. The local drift values of high SBP, a diet high in sodium, and smoking decreased, while the local drift value of lead exposure increased. High SBP was identified as the most significant attributable risk factor for AA mortality burden among both males and females, and smoking was another major attributable risk factor, particularly in males.

Conclusion: From 1990 to 2019, fatality due to AA in China increased notably, but the ASMR showed a decreasing trend. The mortality rate of AA was influenced by age, sex, and attributable risk factors, with elderly male smokers carrying a heavy burden of death. Moreover, tobacco control and treatment of hypertension should be strengthened to reduce the burden and its impact on AA.

{"title":"Trends and risk factors analysis of aortic aneurysm mortality in China over thirty years: based on the global burden of disease 2019 data.","authors":"Hongliang Huang, Liming Tang, Chunjiang Liu, Gan Jin","doi":"10.1093/ehjqcco/qcae084","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae084","url":null,"abstract":"<p><strong>Objectives: </strong>This study aims to analyze the variation in mortality burden of aortic aneurysms (AA) and explore the associated risk factors based on Global Burden of Disease (GBD) 2019 data, investigating the mortality burden of AA in China.</p><p><strong>Methods: </strong>Using GBD 2019 data, the mortality burden of AA in China from 1990 to 2019 was analyzed. The age-period-cohort model was utilized to analyze time trends, period, and cohort effects of 4 attributable risk factors of AA by age.</p><p><strong>Results: </strong>In 2019, the total number of AA deaths in China increased by 136.1% compared to 1990, while the age-standardized mortality rate (ASMR) decreased by 6.8%. Male deaths and ASMR were higher than those of females, and ASMR increased with age. Whether viewed overall (Average Annual Percent Change (AAPC): -0.261, 95% Confidence Interval (CI): -0.383 to -0.138) or by sex (female AAPC: -0.812, 95% CI: -0.977 to -0.646; male AAPC: -0.011, 95% CI: -0.183 to 0.162), the ASMR for AA in China has shown a declining trend since 1990. Attributable risk factors such as high blood pressure, a diet high in sodium, smoking, and lead exposure increase AA mortality with age. Smoking mortality peaks between ages 80-85. The cyclical effect of high blood pressure on AA mortality significantly increases, while the cyclical effects of the other three risk factors decrease. For the population born after 1940, the cohort effect of high systolic blood pressure (SBP), a diet high in sodium, and smoking increased, while the cohort effect of lead exposure decreased. The local drift values of high SBP, a diet high in sodium, and smoking decreased, while the local drift value of lead exposure increased. High SBP was identified as the most significant attributable risk factor for AA mortality burden among both males and females, and smoking was another major attributable risk factor, particularly in males.</p><p><strong>Conclusion: </strong>From 1990 to 2019, fatality due to AA in China increased notably, but the ASMR showed a decreasing trend. The mortality rate of AA was influenced by age, sex, and attributable risk factors, with elderly male smokers carrying a heavy burden of death. Moreover, tobacco control and treatment of hypertension should be strengthened to reduce the burden and its impact on AA.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinicoeconomic burden among heart failure patients with severely reduced ejection fraction after hospital admission: HF-RESTORE.
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-30 DOI: 10.1093/ehjqcco/qcae081
Heidi T May, Jeffrey L Anderson, Michael Butzner, Punag H Divanji, Joseph B Muhlestein

Background: An estimated two-thirds of heart failure (HF) patients with reduced ejection fraction (HFrEF) hospitalized in the United States have a severely reduced left ventricular ejection fraction (LVEF < 30%). Few studies have categorized patients according to their severity of left ventricular dysfunction beyond an LVEF of < 30%.

Methods: Intermountain Health patients (≥18 years), with a primary HF diagnosis, ≥1 inpatient hospitalization with a primary discharge diagnosis of HF, a documented LVEF of < 30%, and a BNP > 100 pg/mL within one year of hospitalization were studied. Patients were stratified by LVEF levels (≤15%, 16-25%, and 26-29%) and evaluated for death, HF hospitalization, healthcare resource utilization, and medical costs.

Results: Overall, 2 184 patients (mean age 64.2 ± 15.5 years, 72.5% male) were stratified by LVEF (≤15%, n = 468 [21.4%]; 16-25%, n = 1399 [64.1%]; and 26-29%, n = 317 [14.5%]). Lower LVEF was associated with younger age, male sex, and fewer comorbidities. Although one-year mortality differed significantly between LVEF stratifications, which remained after adjustment by risk factors (vs. LVEF 26-29% [referent]): ≤15%, hazard ratio (HR)=1.92, p < 0.0001; and 16-25%, HR = 1.42, p = 0.01), mortality was similar by 3-years. HF hospitalizations at 1- and 3-years were similar among LVEF groups. Total HF costs-driven by increased HF outpatient costs-were significantly higher among LVEF of ≤ 15%.

Conclusions: Patients with an LVEF of ≤ 15% had a modestly increased risk of 1-year mortality, as well as significantly higher total HF costs. Patients with HFrEF and a severely reduced LVEF continue to face an increased clinicoeconomic burden, and novel therapies to treat this unmet medical need are warranted.

{"title":"Clinicoeconomic burden among heart failure patients with severely reduced ejection fraction after hospital admission: HF-RESTORE.","authors":"Heidi T May, Jeffrey L Anderson, Michael Butzner, Punag H Divanji, Joseph B Muhlestein","doi":"10.1093/ehjqcco/qcae081","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae081","url":null,"abstract":"<p><strong>Background: </strong>An estimated two-thirds of heart failure (HF) patients with reduced ejection fraction (HFrEF) hospitalized in the United States have a severely reduced left ventricular ejection fraction (LVEF < 30%). Few studies have categorized patients according to their severity of left ventricular dysfunction beyond an LVEF of < 30%.</p><p><strong>Methods: </strong>Intermountain Health patients (≥18 years), with a primary HF diagnosis, ≥1 inpatient hospitalization with a primary discharge diagnosis of HF, a documented LVEF of < 30%, and a BNP > 100 pg/mL within one year of hospitalization were studied. Patients were stratified by LVEF levels (≤15%, 16-25%, and 26-29%) and evaluated for death, HF hospitalization, healthcare resource utilization, and medical costs.</p><p><strong>Results: </strong>Overall, 2 184 patients (mean age 64.2 ± 15.5 years, 72.5% male) were stratified by LVEF (≤15%, n = 468 [21.4%]; 16-25%, n = 1399 [64.1%]; and 26-29%, n = 317 [14.5%]). Lower LVEF was associated with younger age, male sex, and fewer comorbidities. Although one-year mortality differed significantly between LVEF stratifications, which remained after adjustment by risk factors (vs. LVEF 26-29% [referent]): ≤15%, hazard ratio (HR)=1.92, p < 0.0001; and 16-25%, HR = 1.42, p = 0.01), mortality was similar by 3-years. HF hospitalizations at 1- and 3-years were similar among LVEF groups. Total HF costs-driven by increased HF outpatient costs-were significantly higher among LVEF of ≤ 15%.</p><p><strong>Conclusions: </strong>Patients with an LVEF of ≤ 15% had a modestly increased risk of 1-year mortality, as well as significantly higher total HF costs. Patients with HFrEF and a severely reduced LVEF continue to face an increased clinicoeconomic burden, and novel therapies to treat this unmet medical need are warranted.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regional disparities in heart transplant mortality in the United States.
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-28 DOI: 10.1093/ehjqcco/qcae083
Cesar Rodrigo Zoni, Matthew Dean, Laurel A Copeland, Chittoor B Sai Sudhakar, Yazhini Ravi

Background: Mortality after heart transplantation can be influenced by multiple factors. This study analyzed its variation across 4 regions of the United States.

Objective: Analyze the differences in mortality among patients receiving a heart transplant across 4 regions of the United States.

Methods: Organ Procurement and Transplantation Network (OPTN)/United Network for Organ Sharing (UNOS) registry was analyzed for adult heart transplant recipients from 1987-2023. They were divided into 4 regions according to heart transplant recipients' residence: the Northeast, Midwest, South, and West. The endpoint was all-cause mortality.

Results: A total of 33,482 heart transplant recipients were included in the analysis. Baseline characteristics differed by region. The median survival (years) was lower in the South [Northeast 12.9 (6.1-17.9), Midwest 13.1 (6.5-18.1), South 11.6 (5.3-16.8), West 13.6 (7.0-18.6); p<0.0001]. Mortality incidence rate was greater in the South. When compared to the Northeast, in the unadjusted analysis, mortality was higher in the South [HR 1.13 (95%CI 1.07-1.19), p<0.001] and lower in the West [HR 0.89 (95%CI 0.83-0.94), p<0.001]. After adjusting for demographic and clinical variables, only the South retained significant differences [HR 1.17 (95%CI 1.10-1.24), p<0.001]. Mortality significantly increased in all regions after 2018.

Conclusion: Mortality of heart transplant recipients varies across region of residence in the United States. A significant increase in adjusted mortality was observed in the South. These findings suggest that there are regional disparities in the mortality rates of heart transplant recipients.

{"title":"Regional disparities in heart transplant mortality in the United States.","authors":"Cesar Rodrigo Zoni, Matthew Dean, Laurel A Copeland, Chittoor B Sai Sudhakar, Yazhini Ravi","doi":"10.1093/ehjqcco/qcae083","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae083","url":null,"abstract":"<p><strong>Background: </strong>Mortality after heart transplantation can be influenced by multiple factors. This study analyzed its variation across 4 regions of the United States.</p><p><strong>Objective: </strong>Analyze the differences in mortality among patients receiving a heart transplant across 4 regions of the United States.</p><p><strong>Methods: </strong>Organ Procurement and Transplantation Network (OPTN)/United Network for Organ Sharing (UNOS) registry was analyzed for adult heart transplant recipients from 1987-2023. They were divided into 4 regions according to heart transplant recipients' residence: the Northeast, Midwest, South, and West. The endpoint was all-cause mortality.</p><p><strong>Results: </strong>A total of 33,482 heart transplant recipients were included in the analysis. Baseline characteristics differed by region. The median survival (years) was lower in the South [Northeast 12.9 (6.1-17.9), Midwest 13.1 (6.5-18.1), South 11.6 (5.3-16.8), West 13.6 (7.0-18.6); p<0.0001]. Mortality incidence rate was greater in the South. When compared to the Northeast, in the unadjusted analysis, mortality was higher in the South [HR 1.13 (95%CI 1.07-1.19), p<0.001] and lower in the West [HR 0.89 (95%CI 0.83-0.94), p<0.001]. After adjusting for demographic and clinical variables, only the South retained significant differences [HR 1.17 (95%CI 1.10-1.24), p<0.001]. Mortality significantly increased in all regions after 2018.</p><p><strong>Conclusion: </strong>Mortality of heart transplant recipients varies across region of residence in the United States. A significant increase in adjusted mortality was observed in the South. These findings suggest that there are regional disparities in the mortality rates of heart transplant recipients.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness of a novel AI technology to quantify coronary inflammation and cardiovascular risk in patients undergoing routine Coronary Computed Tomography Angiography.
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-28 DOI: 10.1093/ehjqcco/qcae085
Apostolos Tsiachristas, Kenneth Chan, Elizabeth Wahome, Ben Kearns, Parijat Patel, Maria Lyasheva, Nigar Syed, Sam Fry, Thomas Halborg, Henry West, Ed Nicol, David Adlam, Bhavik Modi, Attila Kardos, John P Greenwood, Nikant Sabharwal, Giovanni Luigi De Maria, Shahzad Munir, Elisa McAlindon, Yogesh Sohan, Pete Tomlins, Muhammad Siddique, Cheerag Shirodaria, Ron Blankstein, Milind Desai, Stefan Neubauer, Keith M Channon, John Deanfield, Ron Akehurst, Charalambos Antoniades

Aims: Coronary Computed Tomography Angiography (CCTA) is a first line investigation for chest pain in patients with suspected obstructive coronary artery disease (CAD). However, many acute cardiac events occur in the absence of obstructive CAD. We assessed the lifetime cost-effectiveness of integrating a novel artificial intelligence-enhanced image analysis algorithm (AI-Risk) that stratifies the risk of cardiac events by quantifying coronary inflammation, combined with the extent of coronary artery plaque and clinical risk factors, by analysing images from routine CCTA.

Methods and results: A hybrid decision-tree with population cohort Markov model was developed from 3,393 consecutive patients who underwent routine CCTA for suspected obstructive CAD and followed up for major adverse cardiac events over a median(IQR) of 7.7(6.4-9.1) years. In a prospective real-world evaluation survey of 744 consecutive patients undergoing CCTA for chest pain investigation, the availability of AI-Risk assessment led to treatment initiation or intensification in 45% of patients. In a further prospective study of 1,214 consecutive patients with extensive guideline recommended cardiovascular risk profiling, AI-Risk stratification led to treatment initiation or intensification in 39% of patients beyond the current clinical guideline recommendations. Treatment guided by AI-Risk modelled over a lifetime horizon could lead to fewer cardiac events (relative reductions of 4%, 4%, 11%, and 12% for myocardial infarction, ischaemic stroke, heart failure and cardiac death, respectively). Implementing AI-Risk classification in routine interpretation of CCTA is highly likely to be cost-effective (Incremental cost-effectiveness ratio £1,371-3,244), both in scenarios of current guideline compliance or when applied only to patients without obstructive CAD.

Conclusions: Compared with standard care, the addition of AI-Risk assessment in routine CCTA interpretation is cost effective, by refining risk guided medical management.

{"title":"Cost-effectiveness of a novel AI technology to quantify coronary inflammation and cardiovascular risk in patients undergoing routine Coronary Computed Tomography Angiography.","authors":"Apostolos Tsiachristas, Kenneth Chan, Elizabeth Wahome, Ben Kearns, Parijat Patel, Maria Lyasheva, Nigar Syed, Sam Fry, Thomas Halborg, Henry West, Ed Nicol, David Adlam, Bhavik Modi, Attila Kardos, John P Greenwood, Nikant Sabharwal, Giovanni Luigi De Maria, Shahzad Munir, Elisa McAlindon, Yogesh Sohan, Pete Tomlins, Muhammad Siddique, Cheerag Shirodaria, Ron Blankstein, Milind Desai, Stefan Neubauer, Keith M Channon, John Deanfield, Ron Akehurst, Charalambos Antoniades","doi":"10.1093/ehjqcco/qcae085","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae085","url":null,"abstract":"<p><strong>Aims: </strong>Coronary Computed Tomography Angiography (CCTA) is a first line investigation for chest pain in patients with suspected obstructive coronary artery disease (CAD). However, many acute cardiac events occur in the absence of obstructive CAD. We assessed the lifetime cost-effectiveness of integrating a novel artificial intelligence-enhanced image analysis algorithm (AI-Risk) that stratifies the risk of cardiac events by quantifying coronary inflammation, combined with the extent of coronary artery plaque and clinical risk factors, by analysing images from routine CCTA.</p><p><strong>Methods and results: </strong>A hybrid decision-tree with population cohort Markov model was developed from 3,393 consecutive patients who underwent routine CCTA for suspected obstructive CAD and followed up for major adverse cardiac events over a median(IQR) of 7.7(6.4-9.1) years. In a prospective real-world evaluation survey of 744 consecutive patients undergoing CCTA for chest pain investigation, the availability of AI-Risk assessment led to treatment initiation or intensification in 45% of patients. In a further prospective study of 1,214 consecutive patients with extensive guideline recommended cardiovascular risk profiling, AI-Risk stratification led to treatment initiation or intensification in 39% of patients beyond the current clinical guideline recommendations. Treatment guided by AI-Risk modelled over a lifetime horizon could lead to fewer cardiac events (relative reductions of 4%, 4%, 11%, and 12% for myocardial infarction, ischaemic stroke, heart failure and cardiac death, respectively). Implementing AI-Risk classification in routine interpretation of CCTA is highly likely to be cost-effective (Incremental cost-effectiveness ratio £1,371-3,244), both in scenarios of current guideline compliance or when applied only to patients without obstructive CAD.</p><p><strong>Conclusions: </strong>Compared with standard care, the addition of AI-Risk assessment in routine CCTA interpretation is cost effective, by refining risk guided medical management.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic significance of the estimated pulse wave velocity in critically ill patients with coronary heart disease: analysis from the MIMIC‑IV database. 冠心病重症患者估计脉搏波速度的预后意义:MIMIC-IV 数据库分析。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-14 DOI: 10.1093/ehjqcco/qcae076
Yingzhen Gu, Xiaorong Han, Jinxing Liu, Yifan Li, Zuozhi Li, Wei Zhang, Naqiang Lv, Aimin Dang

Background: There are currently no specialized risk-scoring systems for critically ill patients with coronary heart disease (CHD). Arterial stiffness, as measured by estimated pulse wave velocity (ePWV), has emerged as a potential indicator of mortality or adverse cardiovascular events in individuals with CHD. This study aimed to evaluate the association between ePWV and all-cause mortality among critically ill patients with CHD beyond traditional risk scores.

Methods: This study included 11 001 participants with CHD from the Medical Information Mart for Intensive Care IV, with a one-year follow-up. The primary endpoint was one-year all-cause mortality, and the secondary endpoint was in-hospital mortality.

Results: Elevated ePWV was significantly associated with higher risks of in-hospital (OR 1.15, 95% CI 1.12-1.17, p < 0.001) and one-year (HR 1.21, 95% CI 1.20-1.23, p < 0.001) mortality. These associations remained consistent when adjusted for traditional risk scores and potential confounders. When ePWV was integrated into traditional risk scoring models (OASIS, SOFA score, APSIII, SIRS score, SAPS II, and LODS score), the predictive accuracy (area under the curve: 64.55 to 70.56, 64.32 to 72.51, 72.35 to 75.80, 55.58 to 67.68, 71.27 to 73.53, 67.24 to 73.40, p < 0.001) and reclassification (net reclassification index: 0.230, 0.268, 0.257, 0.255, 0.221, 0.254; integrated discrimination improvement: 0.049, 0.072, 0.054, 0.068, 0.037, 0.061, p < 0.001) of these models significantly improved for one-year mortality. Similar results were also found for in-hospital mortality.

Conclusions: ePWV is a strong independent predictor of both short- and long-term mortality in critically ill patients with CHD. Importantly, integrating ePWV into traditional risk scores significantly boosts the predictive accuracy for one-year and in-hospital all-cause mortality.

背景:目前还没有专门针对冠心病(CHD)重症患者的风险评分系统。以估计脉搏波速度(ePWV)测量的动脉僵化已成为冠心病患者死亡率或不良心血管事件的潜在指标。本研究旨在评估患有冠心病的重症患者中 ePWV 与全因死亡率之间的关系,而非传统的风险评分:这项研究纳入了 11 001 名重症监护医学信息中心 IV 的 CHD 患者,并进行了为期一年的随访。主要终点是一年的全因死亡率,次要终点是院内死亡率:结果:ePWV 升高与较高的院内死亡率风险显著相关(OR 1.15,95% CI 1.12-1.17,p 结论:ePWV 是预测患有心脏病的重症患者短期和长期死亡率的一个强有力的独立指标。重要的是,将 ePWV 纳入传统的风险评分可显著提高对一年死亡率和院内全因死亡率的预测准确性。
{"title":"Prognostic significance of the estimated pulse wave velocity in critically ill patients with coronary heart disease: analysis from the MIMIC‑IV database.","authors":"Yingzhen Gu, Xiaorong Han, Jinxing Liu, Yifan Li, Zuozhi Li, Wei Zhang, Naqiang Lv, Aimin Dang","doi":"10.1093/ehjqcco/qcae076","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae076","url":null,"abstract":"<p><strong>Background: </strong>There are currently no specialized risk-scoring systems for critically ill patients with coronary heart disease (CHD). Arterial stiffness, as measured by estimated pulse wave velocity (ePWV), has emerged as a potential indicator of mortality or adverse cardiovascular events in individuals with CHD. This study aimed to evaluate the association between ePWV and all-cause mortality among critically ill patients with CHD beyond traditional risk scores.</p><p><strong>Methods: </strong>This study included 11 001 participants with CHD from the Medical Information Mart for Intensive Care IV, with a one-year follow-up. The primary endpoint was one-year all-cause mortality, and the secondary endpoint was in-hospital mortality.</p><p><strong>Results: </strong>Elevated ePWV was significantly associated with higher risks of in-hospital (OR 1.15, 95% CI 1.12-1.17, p < 0.001) and one-year (HR 1.21, 95% CI 1.20-1.23, p < 0.001) mortality. These associations remained consistent when adjusted for traditional risk scores and potential confounders. When ePWV was integrated into traditional risk scoring models (OASIS, SOFA score, APSIII, SIRS score, SAPS II, and LODS score), the predictive accuracy (area under the curve: 64.55 to 70.56, 64.32 to 72.51, 72.35 to 75.80, 55.58 to 67.68, 71.27 to 73.53, 67.24 to 73.40, p < 0.001) and reclassification (net reclassification index: 0.230, 0.268, 0.257, 0.255, 0.221, 0.254; integrated discrimination improvement: 0.049, 0.072, 0.054, 0.068, 0.037, 0.061, p < 0.001) of these models significantly improved for one-year mortality. Similar results were also found for in-hospital mortality.</p><p><strong>Conclusions: </strong>ePWV is a strong independent predictor of both short- and long-term mortality in critically ill patients with CHD. Importantly, integrating ePWV into traditional risk scores significantly boosts the predictive accuracy for one-year and in-hospital all-cause mortality.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bacteremia and infective endocarditis following left-sided heart valve surgery. 左侧心脏瓣膜手术后的菌血症和感染性心内膜炎。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-14 DOI: 10.1093/ehjqcco/qcae080
Christine Holgersson, Lauge Østergaard, Eva Havers-Borgersen, Anna Stahl, Katra Hadji-Turdeghal, Amna Alhakak, Marianne Voldstedlund, Morten Smerup, Christian Torp-Pedersen, L Køber, E Fosbøl

Background and aims: In patients undergoing heart valve surgery, subsequent bacteremia and infective endocarditis are feared events. Data on the incidence and bacterial microbiological etiology following left-sided heart valve surgery are sparse.

Methods: Between 2010-2021, all patients undergoing left-sided valve surgery were identified using Danish nationwide registries. Incidence and type bacteremia within one-year post-surgery was analyzed. Secondary outcome of interest was infective endocarditis. Cumulative incidence curves were stratified for bacterial species and for subgroups of interest: type of valve surgery, age, and sex.

Results: A total of 14 935 patients were included, of which 69% were male and the median age was 70.4 years (25th-75th percentile 62.4-76.2 years). The one-year cumulative incidence of bacteremia was 6.1% (95% CI 5.7-6.5%), and the most frequent bacteremia was coagulase-negative staphylococci (27%). More than half of the bacteremia with coagulase-negative staphylococci occurred within 30 days of follow-up. Patients developing bacteremia had a significantly higher Charlson comorbidity score at baseline, more often underwent CABG concomitant to valve surgery, and more often had surgery on both valves. The one-year cumulative incidence of infective endocarditis was 1.5% (95% CI 1.3-1.7), of which 23% were caused by Enterococci, and 22% were blood culture negative. The median time from surgery to infective endocarditis was 109 days.

Conclusions: Bacteremia and infective endocarditis following left-sided heart valve surgery occurred in 6.1% and 1.5% of patients, respectively. The most frequent bacteremia was coagulase-negative staphylococci, and more than half of these occurred within 30 days of surgery. Optimization of prophylactic strategies are warranted.

背景和目的:在接受心脏瓣膜手术的患者中,继发菌血症和感染性心内膜炎是令人担忧的事件。有关左侧心脏瓣膜手术后的发病率和细菌微生物病因的数据非常稀少:方法:2010-2021 年间,通过丹麦全国范围内的登记资料对所有接受左侧瓣膜手术的患者进行了识别。分析了手术后一年内菌血症的发生率和类型。次要研究结果为感染性心内膜炎。根据细菌种类和相关亚组(瓣膜手术类型、年龄和性别)对累积发病率曲线进行了分层:共纳入 14 935 名患者,其中 69% 为男性,中位年龄为 70.4 岁(第 25-75 百分位数为 62.4-76.2 岁)。菌血症的一年累计发病率为 6.1%(95% CI 5.7-6.5%),最常见的菌血症是凝固酶阴性葡萄球菌(27%)。一半以上的凝固酶阴性葡萄球菌菌血症发生在随访的30天内。发生菌血症的患者基线时的Charlson合并症评分明显更高,更多患者在接受瓣膜手术的同时接受了CABG,更多患者同时接受了两个瓣膜的手术。感染性心内膜炎的一年累计发病率为1.5%(95% CI 1.3-1.7),其中23%由肠球菌引起,22%血培养阴性。从手术到感染性心内膜炎的中位时间为109天:结论:左侧心脏瓣膜手术后分别有6.1%和1.5%的患者发生菌血症和感染性心内膜炎。最常见的菌血症是凝固酶阴性葡萄球菌,其中一半以上发生在手术后 30 天内。需要优化预防策略。
{"title":"Bacteremia and infective endocarditis following left-sided heart valve surgery.","authors":"Christine Holgersson, Lauge Østergaard, Eva Havers-Borgersen, Anna Stahl, Katra Hadji-Turdeghal, Amna Alhakak, Marianne Voldstedlund, Morten Smerup, Christian Torp-Pedersen, L Køber, E Fosbøl","doi":"10.1093/ehjqcco/qcae080","DOIUrl":"https://doi.org/10.1093/ehjqcco/qcae080","url":null,"abstract":"<p><strong>Background and aims: </strong>In patients undergoing heart valve surgery, subsequent bacteremia and infective endocarditis are feared events. Data on the incidence and bacterial microbiological etiology following left-sided heart valve surgery are sparse.</p><p><strong>Methods: </strong>Between 2010-2021, all patients undergoing left-sided valve surgery were identified using Danish nationwide registries. Incidence and type bacteremia within one-year post-surgery was analyzed. Secondary outcome of interest was infective endocarditis. Cumulative incidence curves were stratified for bacterial species and for subgroups of interest: type of valve surgery, age, and sex.</p><p><strong>Results: </strong>A total of 14 935 patients were included, of which 69% were male and the median age was 70.4 years (25th-75th percentile 62.4-76.2 years). The one-year cumulative incidence of bacteremia was 6.1% (95% CI 5.7-6.5%), and the most frequent bacteremia was coagulase-negative staphylococci (27%). More than half of the bacteremia with coagulase-negative staphylococci occurred within 30 days of follow-up. Patients developing bacteremia had a significantly higher Charlson comorbidity score at baseline, more often underwent CABG concomitant to valve surgery, and more often had surgery on both valves. The one-year cumulative incidence of infective endocarditis was 1.5% (95% CI 1.3-1.7), of which 23% were caused by Enterococci, and 22% were blood culture negative. The median time from surgery to infective endocarditis was 109 days.</p><p><strong>Conclusions: </strong>Bacteremia and infective endocarditis following left-sided heart valve surgery occurred in 6.1% and 1.5% of patients, respectively. The most frequent bacteremia was coagulase-negative staphylococci, and more than half of these occurred within 30 days of surgery. Optimization of prophylactic strategies are warranted.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Behavioural digital biomarkers enable real-time monitoring of patient-reported outcomes: a substudy of the multicentre, prospective observational SafeHeart study. 行为数字生物标志物能够实时监测患者报告的结果:多中心前瞻性观察性SafeHeart研究的一个子研究。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-13 DOI: 10.1093/ehjqcco/qcad069
Maarten Z H Kolk, Diana M Frodi, Joss Langford, Caroline J Meskers, Tariq O Andersen, Peter Karl Jacobsen, Niels Risum, Hanno L Tan, Jesper H Svendsen, Reinoud E Knops, Søren Z Diederichsen, Fleur V Y Tjong

Aims: Patient-reported outcome measures (PROMs) serve multiple purposes, including shared decision-making and patient communication, treatment monitoring, and health technology assessment. Patient monitoring using PROMs is constrained by recall and non-response bias, respondent burden, and missing data. We evaluated the potential of behavioural digital biomarkers obtained from a wearable accelerometer to achieve personalized predictions of PROMs.

Methods and results: Data from the multicentre, prospective SafeHeart study conducted at Amsterdam University Medical Center in the Netherlands and Copenhagen University Hospital, Rigshospitalet in Copenhagen, Denmark, were used. The study enrolled patients with an implantable cardioverter defibrillator between May 2021 and September 2022 who then wore wearable devices with raw acceleration output to capture digital biomarkers reflecting physical behaviour. To collect PROMs, patients received the Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQoL 5-Dimensions 5-Level (EQ5D-5L) questionnaire at two instances: baseline and after six months. Multivariable Tobit regression models were used to explore associations between digital biomarkers and PROMs, specifically whether digital biomarkers could enable PROM prediction. The study population consisted of 303 patients (mean age 62.9 ± 10.9 years, 81.2% male). Digital biomarkers showed significant correlations to patient-reported physical and social limitations, severity and frequency of symptoms, and quality of life. Prospective validation of the Tobit models indicated moderate correlations between the observed and predicted scores for KCCQ [concordance correlation coefficient (CCC) = 0.49, mean difference: 1.07 points] and EQ5D-5L (CCC = 0.38, mean difference: 0.02 points).

Conclusion: Wearable digital biomarkers correlate with PROMs, and may be leveraged for real-time prediction. These findings hold promise for monitoring of PROMs through wearable accelerometers.

患者报告的结果测量(PROMs)具有多种目的,包括共同决策和患者沟通、治疗监测和卫生技术评估。使用prom进行患者监测受到回忆和非反应偏倚、应答者负担和数据缺失的限制。我们评估了从可穿戴加速度计获得的行为数字生物标志物的潜力,以实现对prom的个性化预测。方法:数据来自荷兰阿姆斯特丹大学医学中心和丹麦哥本哈根的Rigshospitalet哥本哈根大学医院进行的多中心前瞻性安全心脏研究。该研究在2021年5月至2022年9月期间招募了带有植入式心律转复除颤器(ICD)的患者,然后他们佩戴具有原始加速度输出的可穿戴设备,以捕捉反映身体行为的数字生物标志物。为收集PROMs,患者分别接受KCCQ和eq5d - 5l问卷;基线和6个月后。多变量Tobit回归模型用于探索数字生物标志物与PROM之间的关系,特别是数字生物标志物是否能够预测PROM。结果:研究人群包括303例患者(平均年龄62.9±10.9岁,男性81.2%)。数字生物标志物显示与患者报告的身体和社会限制、症状的严重程度和频率以及生活质量显著相关。Tobit模型的前瞻性验证表明,KCCQ(一致性相关系数(CCC) = 0.49,平均差值为1.07分)和eq5d - 5l (CCC = 0.38,平均差值为0.02分)的观察值与预测值之间存在中度相关性。结论:可穿戴数字生物标志物与prom相关,可用于实时预测。这些发现为通过可穿戴加速计监测prom带来了希望。
{"title":"Behavioural digital biomarkers enable real-time monitoring of patient-reported outcomes: a substudy of the multicentre, prospective observational SafeHeart study.","authors":"Maarten Z H Kolk, Diana M Frodi, Joss Langford, Caroline J Meskers, Tariq O Andersen, Peter Karl Jacobsen, Niels Risum, Hanno L Tan, Jesper H Svendsen, Reinoud E Knops, Søren Z Diederichsen, Fleur V Y Tjong","doi":"10.1093/ehjqcco/qcad069","DOIUrl":"10.1093/ehjqcco/qcad069","url":null,"abstract":"<p><strong>Aims: </strong>Patient-reported outcome measures (PROMs) serve multiple purposes, including shared decision-making and patient communication, treatment monitoring, and health technology assessment. Patient monitoring using PROMs is constrained by recall and non-response bias, respondent burden, and missing data. We evaluated the potential of behavioural digital biomarkers obtained from a wearable accelerometer to achieve personalized predictions of PROMs.</p><p><strong>Methods and results: </strong>Data from the multicentre, prospective SafeHeart study conducted at Amsterdam University Medical Center in the Netherlands and Copenhagen University Hospital, Rigshospitalet in Copenhagen, Denmark, were used. The study enrolled patients with an implantable cardioverter defibrillator between May 2021 and September 2022 who then wore wearable devices with raw acceleration output to capture digital biomarkers reflecting physical behaviour. To collect PROMs, patients received the Kansas City Cardiomyopathy Questionnaire (KCCQ) and EuroQoL 5-Dimensions 5-Level (EQ5D-5L) questionnaire at two instances: baseline and after six months. Multivariable Tobit regression models were used to explore associations between digital biomarkers and PROMs, specifically whether digital biomarkers could enable PROM prediction. The study population consisted of 303 patients (mean age 62.9 ± 10.9 years, 81.2% male). Digital biomarkers showed significant correlations to patient-reported physical and social limitations, severity and frequency of symptoms, and quality of life. Prospective validation of the Tobit models indicated moderate correlations between the observed and predicted scores for KCCQ [concordance correlation coefficient (CCC) = 0.49, mean difference: 1.07 points] and EQ5D-5L (CCC = 0.38, mean difference: 0.02 points).</p><p><strong>Conclusion: </strong>Wearable digital biomarkers correlate with PROMs, and may be leveraged for real-time prediction. These findings hold promise for monitoring of PROMs through wearable accelerometers.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138498144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the method of calculating 30-day readmission rate after hospitalization for heart failure. Data from the VancOuver CoastAL Acute Heart Failure (VOCAL-AHF) registry. 心衰住院后 30 天再入院率计算方法的影响。数据来自 VancOuver CoastAL 急性心力衰竭(VOCAL-AHF)登记处。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-13 DOI: 10.1093/ehjqcco/qcae026
Samaneh Salimian, Sean A Virani, Thomas M Roston, Ren Jie Robert Yao, Ricky D Turgeon, Justin Ezekowitz, Nathaniel M Hawkins

Background: Thirty-day readmission rate after heart failure (HF) hospitalization is widely used to evaluate healthcare quality. Methodology may substantially influence estimated rates. We assessed the impact of different definitions on HF and all-cause readmission rates.

Methods: Readmission rates were examined in 1835 patients discharged following HF hospitalization using 64 unique definitions derived from five methodological factors: (1) International Classification of Diseases-10 codes (broad vs. narrow), (2) index admission selection (single admission only first-in-year vs. random sample; or multiple admissions in year with vs. without 30-day blanking period), (3) variable denominator (number alive at discharge vs. number alive at 30 days), (4) follow-up period start (discharge date vs. day following discharge), and (5) annual reference period (calendar vs. fiscal). The impact of different factors was assessed using linear regression.

Results: The calculated 30-day readmission rate for HF varied more than two-fold depending solely on the methodological approach (6.5-15.0%). All-cause admission rates exhibited similar variation (18.8-29.9%). The highest rates included all consecutive index admissions (HF 11.1-15.0%, all-cause 24.0-29.9%), and the lowest only one index admission per patient per year (HF 6.5-11.3%, all-cause 18.8-22.7%). When including multiple index admissions and compared with blanking the 30-day post-discharge, not blanking was associated with 2.3% higher readmission rates. Selecting a single admission per year with a first-in-year approach lowered readmission rates by 1.5%, while random-sampling admissions lowered estimates further by 5.2% (P < 0.001).

Conclusion: Calculated 30-day readmission rates varied more than two-fold by altering methods. Transparent and consistent methods are needed to ensure reproducible and comparable reporting.

背景:心力衰竭(HF)住院后 30 天再入院率被广泛用于评估医疗质量。方法可能会对估计的再入院率产生重大影响。我们评估了不同定义对心衰和全因再入院率的影响:对 1835 名心房颤动住院后出院的患者的再入院率进行了研究,使用了从五个方法因素中得出的 64 个独特定义:(1)ICD-10编码(广义与狭义),(2)指标入院选择(单次入院仅为当年首次入院与随机抽样;或当年多次入院有30天空白期与无30天空白期),(3)可变分母(出院时存活人数与30天时存活人数),(4)随访期开始(出院日期与出院次日),(5)年度参照期(日历期与财政期)。使用线性回归评估了不同因素的影响:结果:计算得出的高血压 30 天再入院率因方法不同而相差 2 倍多(6.5% 至 15.0%)。全因入院率也有类似的变化(18.8% 到 29.9%)。最高入院率包括所有连续指数入院(高频 11.1-15.0%,全因 24.0-29.9%),最低入院率为每位患者每年只有一次指数入院(高频 6.5-11.3%,全因 18.8-22.7%)。如果包括多次指标入院并与出院后 30 天内空白相比,不空白与再入院率增加 2.3% 相关。采用 "年中第一例 "的方法每年选择一次入院,可将再入院率降低 1.5%,而随机抽样入院则可将估计值进一步降低 5.2%(p 结论:不同方法计算出的 30 天再入院率相差超过 2 倍。为确保报告的可重复性和可比性,需要采用透明、一致的方法。
{"title":"Impact of the method of calculating 30-day readmission rate after hospitalization for heart failure. Data from the VancOuver CoastAL Acute Heart Failure (VOCAL-AHF) registry.","authors":"Samaneh Salimian, Sean A Virani, Thomas M Roston, Ren Jie Robert Yao, Ricky D Turgeon, Justin Ezekowitz, Nathaniel M Hawkins","doi":"10.1093/ehjqcco/qcae026","DOIUrl":"10.1093/ehjqcco/qcae026","url":null,"abstract":"<p><strong>Background: </strong>Thirty-day readmission rate after heart failure (HF) hospitalization is widely used to evaluate healthcare quality. Methodology may substantially influence estimated rates. We assessed the impact of different definitions on HF and all-cause readmission rates.</p><p><strong>Methods: </strong>Readmission rates were examined in 1835 patients discharged following HF hospitalization using 64 unique definitions derived from five methodological factors: (1) International Classification of Diseases-10 codes (broad vs. narrow), (2) index admission selection (single admission only first-in-year vs. random sample; or multiple admissions in year with vs. without 30-day blanking period), (3) variable denominator (number alive at discharge vs. number alive at 30 days), (4) follow-up period start (discharge date vs. day following discharge), and (5) annual reference period (calendar vs. fiscal). The impact of different factors was assessed using linear regression.</p><p><strong>Results: </strong>The calculated 30-day readmission rate for HF varied more than two-fold depending solely on the methodological approach (6.5-15.0%). All-cause admission rates exhibited similar variation (18.8-29.9%). The highest rates included all consecutive index admissions (HF 11.1-15.0%, all-cause 24.0-29.9%), and the lowest only one index admission per patient per year (HF 6.5-11.3%, all-cause 18.8-22.7%). When including multiple index admissions and compared with blanking the 30-day post-discharge, not blanking was associated with 2.3% higher readmission rates. Selecting a single admission per year with a first-in-year approach lowered readmission rates by 1.5%, while random-sampling admissions lowered estimates further by 5.2% (P < 0.001).</p><p><strong>Conclusion: </strong>Calculated 30-day readmission rates varied more than two-fold by altering methods. Transparent and consistent methods are needed to ensure reproducible and comparable reporting.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11398898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management and outcome in foreign-born vs native-born patients with myocardial infarction in Sweden. 瑞典心肌梗塞患者中外国出生者与本地出生者的管理和预后。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-13 DOI: 10.1093/ehjqcco/qcae020
Sammy Zwackman, Jenny Häggström, Emil Hagström, Tomas Jernberg, Jan-Erik Karlsson, Sofia Sederholm Lawesson, Margret Leosdottir, Annica Ravn-Fischer, Marie Eriksson, Joakim Alfredsson

Aims: Previous studies on disparities in healthcare and outcomes have shown conflicting results. The aim of this study was to assess differences in baseline characteristics, management, and outcomes in myocardial infarction (MI) patients, by country of birth.

Methods and results: In total, 194 259 MI patients (64% male, 15% foreign-born) from the nationwide SWEDEHEART (The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) registry were included and compared by geographic region of birth. The primary outcome was 1-year major adverse cardiovascular events (MACEs) including all-cause death, MI, and stroke. Secondary outcomes were long-term MACE (up to 12 years), the individual components of MACE, 30-day mortality, management, and risk factors. Logistic regression, Cox proportional hazard models, and propensity score match (PSM), accounting for baseline differences, were used. Foreign-born patients were younger, often male, and had a higher cardiovascular (CV) risk factor burden, including smoking, diabetes, and hypertension. In PSM analyses, Asia-born patients had higher likelihood of revascularization [odds ratio 1.16, 95% confidence interval (CI) 1.04-1.30], statins and beta-blocker prescription at discharge, and a 34% lower risk of 30-day mortality. Furthermore, no statistically significant differences were found in primary outcomes except for Asia-born patients having lower risk of 1-year MACE [hazard ratio (HR) 0.85, 95% CI 0.73-0.98], driven by lower mortality (HR 0.72, 95% CI 0.57-0.91). The results persisted over the long-term follow-up.

Conclusion: This study shows that in a system with universal healthcare coverage in which acute and secondary preventive treatments do not differ by country of birth, foreign-born patients, despite higher CV risk factor burden, will do at least as well as native-born patients.

背景:以往关于医疗保健和治疗效果差异的研究显示了相互矛盾的结果。本研究旨在评估心肌梗死(MI)患者的基线特征、管理和预后在不同出生国家的差异:共纳入了来自全国 SWEDEHEART 登记处的 194 259 名心肌梗死患者(64% 为男性,15% 为外国出生者),并按出生地进行了比较。主要结果是一年的主要心血管不良事件(MACE),包括全因死亡、心肌梗死和中风。次要结果是长期 MACE(长达 12 年)、MACE 的各个组成部分、30 天死亡率、管理和风险因素。研究采用了逻辑回归、考克斯比例危险模型和倾向评分匹配(PSM),并考虑了基线差异:结果:外国出生的患者更年轻,通常为男性,心血管(CV)风险因素负担更重,包括吸烟、糖尿病和高血压。在 PSM 分析中,亚洲出生的患者接受血管再通手术的可能性更高(OR 1.16,95% CI 1.04-1.30),出院时服用他汀类药物和受体阻滞剂的比例更高,30 天死亡风险降低了 34%。此外,除了亚洲出生的患者因死亡率较低(HR 0.72,95% CI 0.57-0.91)而降低了一年期MACE风险(HR 0.85,95% CI 0.73-0.98)外,其他主要结果均无统计学意义上的显著差异。这些结果在长期随访中持续存在:这项研究表明,在一个全民医疗保险体系中,急性和二级预防性治疗并不因出生国不同而有所区别,外国出生的患者尽管有较高的心血管风险因素负担,但其治疗效果至少与本地出生的患者一样好。
{"title":"Management and outcome in foreign-born vs native-born patients with myocardial infarction in Sweden.","authors":"Sammy Zwackman, Jenny Häggström, Emil Hagström, Tomas Jernberg, Jan-Erik Karlsson, Sofia Sederholm Lawesson, Margret Leosdottir, Annica Ravn-Fischer, Marie Eriksson, Joakim Alfredsson","doi":"10.1093/ehjqcco/qcae020","DOIUrl":"10.1093/ehjqcco/qcae020","url":null,"abstract":"<p><strong>Aims: </strong>Previous studies on disparities in healthcare and outcomes have shown conflicting results. The aim of this study was to assess differences in baseline characteristics, management, and outcomes in myocardial infarction (MI) patients, by country of birth.</p><p><strong>Methods and results: </strong>In total, 194 259 MI patients (64% male, 15% foreign-born) from the nationwide SWEDEHEART (The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) registry were included and compared by geographic region of birth. The primary outcome was 1-year major adverse cardiovascular events (MACEs) including all-cause death, MI, and stroke. Secondary outcomes were long-term MACE (up to 12 years), the individual components of MACE, 30-day mortality, management, and risk factors. Logistic regression, Cox proportional hazard models, and propensity score match (PSM), accounting for baseline differences, were used. Foreign-born patients were younger, often male, and had a higher cardiovascular (CV) risk factor burden, including smoking, diabetes, and hypertension. In PSM analyses, Asia-born patients had higher likelihood of revascularization [odds ratio 1.16, 95% confidence interval (CI) 1.04-1.30], statins and beta-blocker prescription at discharge, and a 34% lower risk of 30-day mortality. Furthermore, no statistically significant differences were found in primary outcomes except for Asia-born patients having lower risk of 1-year MACE [hazard ratio (HR) 0.85, 95% CI 0.73-0.98], driven by lower mortality (HR 0.72, 95% CI 0.57-0.91). The results persisted over the long-term follow-up.</p><p><strong>Conclusion: </strong>This study shows that in a system with universal healthcare coverage in which acute and secondary preventive treatments do not differ by country of birth, foreign-born patients, despite higher CV risk factor burden, will do at least as well as native-born patients.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140058977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Remnant cholesterol and risk of premature mortality: an analysis from a nationwide prospective cohort study. 残留胆固醇与过早死亡风险:一项全国性前瞻性队列研究的分析。
IF 4.8 2区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-09-13 DOI: 10.1093/ehjqcco/qcad071
Likang Li, Jun Lai, Jingyi Zhang, Harriette G C Van Spall, Lehana Thabane, Gregory Y H Lip, Guowei Li

Aims: To explore the relationship between remnant cholesterol (RC) and the risk of premature mortality as well as life expectancy in the general population.

Methods: We included a total of 428 804 participants from the UK Biobank for analyses. Equivalent population percentiles approach based on the low-density lipoprotein cholesterol cut-off points was performed to categorize participants into three RC groups: low (with a mean RC of 0.34 mmol/L), moderate (0.53 mmol/L), and high (1.02 mmol/L). We used multivariable Cox proportional hazards models to evaluate the relationship between RC groups and the risk of premature mortality (defined as death before age 75 years). Life table methods were used to estimate life expectancy by RC groups.

Results: During a median follow-up of 12.1 years (Q1-Q3 11.0-13.0), there were 23 693 all-cause premature deaths documented, with an incidence of 4.83 events per 1000 person-years [95% confidence interval (CI): 4.77-4.89]. Compared with the low RC group, the moderate RC group was associated with a 9% increased risk of all-cause premature mortality [hazard ratio (HR) = 1.09, 95% CI: 1.05-1.14], while the high RC group had an 11% higher risk (HR = 1.11, 95% CI: 1.07-1.16). At the age of 50 years, high RC group was associated with an average 2.2 lower years of life expectancy for females, and an average 0.1 lower years of life expectancy for males when compared with their counterparts in the low RC group.

Conclusions: Elevated RC was significantly related to an increased risk of premature mortality and a reduced life expectancy. Premature death in the general population would benefit from measurement to aid risk stratification and proactive management of RC to improve cardiovascular risk prevention efforts.

目的:探讨残余胆固醇(RC)与过早死亡风险以及普通人群预期寿命之间的关系:我们纳入了英国生物库中的 428,804 名参与者进行分析。我们采用基于低密度脂蛋白胆固醇(LDL-C)临界点的等效人口百分位数法,将参与者分为三个RC组:低(平均RC为0.34 mmol/L)、中(0.53 mmol/L)和高(1.02 mmol/L)。我们使用多变量 Cox 比例危险模型来评估 RC 组别与过早死亡风险(定义为 75 岁前死亡)之间的关系。我们还使用生命表方法估算了各 RC 组的预期寿命:中位随访期为 12.1 年(Q1 - Q3:11.0 - 13.0),共记录了 23,693 例全因过早死亡,发病率为每千人年 4.83 例(95% 置信区间 [CI]:4.77 - 4.89)。与低 RC 组相比,中度 RC 组的全因过早死亡风险增加了 9%(危险比 [HR] = 1.09,95% 置信区间 [CI]:1.05 - 1.14),而高度 RC 组的风险增加了 11%(危险比 = 1.11,95% 置信区间 [CI]:1.07 - 1.16)。在50岁时,与低RC组相比,高RC组女性平均预期寿命减少2.2年,男性平均预期寿命减少0.1年:RC 升高与过早死亡风险增加和预期寿命缩短有很大关系。对一般人群的过早死亡进行测量,有助于风险分层和积极管理 RC,从而改善心血管风险预防工作。
{"title":"Remnant cholesterol and risk of premature mortality: an analysis from a nationwide prospective cohort study.","authors":"Likang Li, Jun Lai, Jingyi Zhang, Harriette G C Van Spall, Lehana Thabane, Gregory Y H Lip, Guowei Li","doi":"10.1093/ehjqcco/qcad071","DOIUrl":"10.1093/ehjqcco/qcad071","url":null,"abstract":"<p><strong>Aims: </strong>To explore the relationship between remnant cholesterol (RC) and the risk of premature mortality as well as life expectancy in the general population.</p><p><strong>Methods: </strong>We included a total of 428 804 participants from the UK Biobank for analyses. Equivalent population percentiles approach based on the low-density lipoprotein cholesterol cut-off points was performed to categorize participants into three RC groups: low (with a mean RC of 0.34 mmol/L), moderate (0.53 mmol/L), and high (1.02 mmol/L). We used multivariable Cox proportional hazards models to evaluate the relationship between RC groups and the risk of premature mortality (defined as death before age 75 years). Life table methods were used to estimate life expectancy by RC groups.</p><p><strong>Results: </strong>During a median follow-up of 12.1 years (Q1-Q3 11.0-13.0), there were 23 693 all-cause premature deaths documented, with an incidence of 4.83 events per 1000 person-years [95% confidence interval (CI): 4.77-4.89]. Compared with the low RC group, the moderate RC group was associated with a 9% increased risk of all-cause premature mortality [hazard ratio (HR) = 1.09, 95% CI: 1.05-1.14], while the high RC group had an 11% higher risk (HR = 1.11, 95% CI: 1.07-1.16). At the age of 50 years, high RC group was associated with an average 2.2 lower years of life expectancy for females, and an average 0.1 lower years of life expectancy for males when compared with their counterparts in the low RC group.</p><p><strong>Conclusions: </strong>Elevated RC was significantly related to an increased risk of premature mortality and a reduced life expectancy. Premature death in the general population would benefit from measurement to aid risk stratification and proactive management of RC to improve cardiovascular risk prevention efforts.</p>","PeriodicalId":11869,"journal":{"name":"European Heart Journal - Quality of Care and Clinical Outcomes","volume":null,"pages":null},"PeriodicalIF":4.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138797997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Heart Journal - Quality of Care and Clinical Outcomes
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1